ClinVar Miner

Submissions for variant NM_000169.3(GLA):c.136C>T (p.His46Tyr)

dbSNP: rs1928582757
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001280630 SCV001467861 pathogenic Fabry disease 2020-12-03 criteria provided, single submitter clinical testing Variant summary: GLA c.136C>T (p.His46Tyr) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 183425 control chromosomes. c.136C>T has been reported in the literature in multiple individuals affected with Fabry Disease (example, Blaydon_2001, Whitfield_2005, Benjamin_2009, Shabbeer_2002, Wu_2011, Nowak_2019). These data indicate that the variant is very likely to be associated with disease. Several publications report experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity (example, Whitfield_2005) and no response to the pharmacological chaperone 1-deoxygalactonojirimycin (DGJ) (example, Benjamin_2009). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.